GlobeNewswire by notified

Reminder: Program for the publication of Yara International ASA first quarter results 2022

Share

The Yara International ASA first quarter 2022 results will be published on Wednesday 27 April 2022at08:00 CEST.


An on-line presentation will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether. The presentation will be held in English.

The report, presentation and webcast will be available at the above mentioned times at:
yara.com/investor-relations/latest-quarterly-report/

There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management.

Please use this link for online registration for the conference call:

http://emea.directeventreg.com/registration/4661876

  • Participants must register in advance of the conference using the link provided. Upon registering, you will be provided with participant dial-in numbers, Direct Event passcode and unique registrant ID.
  • In the 10 minutes prior to call start time, you will need to use the conference access information provided in the email received at the point of registering.
  • Note: Due to regional restrictions some participants may receive operator assistance when joining this conference call and will not be automatically connected.


A replay of the conference call will be available from 27 April 18:00 CEST until 18 May 18:00 CEST. Please use the Dial-in Numbers listed below and Conference ID 4661876:
Norway: 21034235
UK FreeCall: 08082380667
USA: 1(917)677-7532
International: 44(0)3333009785


Yours faithfully
for Yara International ASA

Silje Ingeberg Nygaard
Head of Investor Relations


About Yara

Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a nature positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable food value chain.

To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming and work closely with partners throughout the food value chain to improve the efficiency and sustainability of food production. Through our focus on clean ammonia production, we aim to enable the hydrogen economy, driving a green transition of shipping, fertilizer production and other energy intensive industries.

Founded in 1905 to solve the emerging famine in Europe, Yara has established a unique position as the industry’s only global crop nutrition company. We operate an integrated business model with around 17,000 employees and operations in over 60 countries, with a proven track record of strong returns. In 2021, Yara reported revenues of USD 16.6 billion.

www.yara.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Global COVID-19 Memorial Will Honor Pandemic Frontline & Essential Workers24.4.2024 16:18:34 CEST | Press release

CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) -- A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience draws attention to the enormous sacrifices made by these workers and the stress they encountered. Further, the COVID-19Monument pays tribute to those who lost the battle to COVID-19, now more than seven million individuals. Accessible 24/7, the monument park and website will serve as a gathering space of healing, reflection, & wellness. The website will invite participation from all, and preserve the oral history of essential workers, pandemic survivors (especially those suffering from Long-COVID) and serve as a permanent memorial to lost loved ones. Sally Metzler, Ph.D., the Chair of the Commission, emphasized the epic nature of the impact of the pandemic, “No other event in recent history has t

Fly Play hf.: Increase of share capital24.4.2024 16:16:35 CEST | Press release

Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a meeting today to increase the Company's share capital by issuing 1,023,155,559 new shares, each with a nominal value of 1 ISK. The new shares will be delivered to investors on April 29, 2024, and admission to trading of the new shares on Nasdaq First North Growth Market Iceland is scheduled to commence on the same day under the symbol PLAY (ISIN: IS0000032936). Following the share capital increase, PLAY has 1,891,598,895 shares outstanding.

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting24.4.2024 16:14:55 CEST | Press release

NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022. The poster presentation features key findings and analyses after a minimum 18-month follow-up of the patients in the trial. Presentation Details: Abstract Num

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo

HiddenA line styled icon from Orion Icon Library.Eye